Also called: ART · Antiretroviral therapy
Important: This page is general information, not medical advice. It does not recommend or prescribe any treatment. Always consult your doctor or pharmacist before starting, stopping or changing any medicine.
About HIV Medicines
HIV stands for human immunodeficiency virus. It harms your immune system by destroying CD4 cells. These are a type of white blood cells that fight infection. The loss of these cells makes it hard for your body to fight off infections and certain HIV-related cancers.
Without treatment, HIV can gradually destroy the immune system and advance to AIDS. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS.
The treatment of HIV with medicines is called antiretroviral therapy (ART). It involves taking a combination of medicines every day. ART is recommended for everyone who has HIV. The medicines do not cure HIV infection, but help people with HIV live longer, healthier lives. They also reduce the risk of spreading the virus to others.
HIV medicines reduce the amount of HIV (viral load) in your body, which helps by:
- Giving your immune system a chance to recover. Even though there is still some HIV in your body, your immune system should be strong enough to fight off infections and certain HIV-related cancers.
- Reducing the risk that you will spread HIV to others.
There are many different types (called classes) of HIV medicines. Some work by blocking or changing enzymes that HIV needs to make copies of itself. This prevents HIV from copying itself, which reduces the amount of HIV in the body. Several types of medicines do this:
- Nucleoside reverse transcriptase inhibitors (NRTIs) block an enzyme called reverse transcriptase
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and later change reverse transcriptase
- Integrase inhibitors, also called integrase strand transfer inhibitors (INSTIs), block an enzyme called integrase
- Protease inhibitors (PIs) block an enzyme called protease
Some types of HIV medicines interfere with HIV's ability to infect CD4 immune system cells:
- Fusion inhibitors block HIV from entering the cells
- CCR5 antagonists and post-attachment inhibitors block different molecules on the CD4 cells. To infect a cell, HIV has to bind to two types of molecules on the cell's surface. Blocking either of these molecules prevents HIV from entering the cells.
- Attachment inhibitors bind to a specific protein on the outer surface of HIV. This prevents HIV from entering the cell.
Pharmacokinetic enhancers are another type of medicine. They are sometimes taken along with certain other HIV medicines. Pharmacokinetic enhancers increase the effectiveness of the other medicine. They work by slowing the breakdown of the other medicine. This allows that medicine to stay in the body longer at a higher concentration.
There are also multidrug combinations, which include a combination of two or more different types of HIV medicines.
It's important to start taking HIV medicines as soon as possible after your diagnosis, especially if you:
- Are pregnant
- Have AIDS
- Have certain HIV-related illnesses and infections
- Have an early HIV infection (the first 6 months after infection with HIV)
You and your health care provider will work together to come up with a personal treatment plan. This plan will be based on many factors, including:
- The possible side effects of HIV medicines
- Potential drug interactions with any other medicines you take
- How many medicines you will need to take every day
- Any other health problems you may have
It's important to take your medicines every day, according to the instructions from your provider. If you miss doses or don't follow a regular schedule, your treatment may not work, and the HIV virus may become resistant to the medicines.
HIV medicines can cause side effects. Most of these side effects are manageable, but a few can be serious. Tell your provider about any side effects that you are having. Don't stop taking your medicine without first talking to your provider. There may be steps you can take to help manage the side effects. In some cases, your provider may decide to change your medicines.
HIV medicines are not just used for treatment. Some people take them to prevent HIV. PrEP (pre-exposure prophylaxis) is for people who don't already have HIV but are at very high risk of getting it. PEP (post-exposure prophylaxis) is for people who have possibly been exposed to HIV.
It sits within Immune System and Drug Therapy.
The lead U.S. institute for this subject is the National Institute of Allergy and Infectious Diseases.
When to speak to someone. Reading about a topic cannot tell you whether it applies to you. Speak to a doctor or pharmacist if symptoms are severe, sudden, getting worse, or simply not going away — and seek emergency care immediately for chest pain, breathing difficulty, sudden weakness or confusion, or a serious allergic reaction.
Research on HIV Medicines
1,783 studies areregistered for this condition on ClinicalTrials.gov, the U.S. National Library of Medicine's public registry. A selection is below — the links go straight to the registry entry, not to a summary of ours.
What a registered study does and does not mean. Registration means a study exists and has been declared publicly. It says nothing about whether the treatment being tested works, is safe, or is available to you. Many studies find no benefit — that is what research is for. Never seek out an experimental treatment on the strength of a registry entry alone.
Research currently under way
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyNational Institute of Allergy and Infectious Diseases (NIAID)
- Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose RiskApril M Young
- Digital PrEP Micro-Intervention for PWUD in KazakhstanYale University
- Virtual Reality (VR) Self-Hypnosis SoftwareIcahn School of Medicine at Mount Sinai
- Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support ServicesYale University
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York CityNorth Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Research already completed
- SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian YouthDuke University
- A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without IbalizumabTheratechnologies
- MAPS PrEP Van StudyDuke University
- New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis PneumoniaNational Institute of Allergy and Infectious Diseases (NIAID)
- Health Outcomes by Neighborhood - BaltimoreNational Institute on Drug Abuse (NIDA)
- SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use DisorderBrigham and Women's Hospital
Study data from ClinicalTrials.gov, a service of the U.S. National Library of Medicine. Retrieved 2026-07-30. Registry entries are supplied by study sponsors and investigators; ClinicalTrials.gov does not verify their scientific validity. PocketsInfo is not affiliated with, and not endorsed by, the NLM or the NIH.
Where to read more
Rather than paraphrase, we point you to the primary sources. Every link below is to a government health agency, a national institute or a recognised medical body — grouped by what you are trying to find out.
Start Here
- Drug DatabaseHIV.gov
- FDA-Approved HIV MedicinesNational Institutes of Health, Office of AIDS Research
- Get the Facts about HIV MedicinesNational Library of Medicine
Learn More
- Drugs that Fight HIVNational Institute of Allergy and Infectious Diseases
Diagnosis and Tests
- Pharmacogenetic TestsNational Library of Medicine
Related Issues
- Drug ResistanceNational Institutes of Health, Office of AIDS Research
- Following an HIV Treatment Regimen: Steps to Take Before and After Starting HIV MedicinesNational Institutes of Health, Office of AIDS Research
- HIV and DiabetesNational Institutes of Health, Office of AIDS Research
- HIV and HepatotoxicityNational Institutes of Health, Office of AIDS Research
- HIV and Lactic AcidosisNational Institutes of Health, Office of AIDS Research
- HIV and LipodystrophyNational Institutes of Health, Office of AIDS Research
- HIV and OsteoporosisNational Institutes of Health, Office of AIDS Research
- HIV and RashNational Institutes of Health, Office of AIDS Research
- HIV Medicines and Side EffectsNational Institutes of Health, Office of AIDS Research
- HIV Treatment AdherenceNational Institutes of Health, Office of AIDS Research
- HIV: PrEP and PEP: MedlinePlus Health TopicNational Library of Medicine
- What to Start: Choosing an HIV Treatment RegimenNational Institutes of Health, Office of AIDS Research
- When to Start HIV MedicinesNational Institutes of Health, Office of AIDS Research
Clinical Trials
- ClinicalTrials.gov: Highly Active Antiretroviral Therapy (HAART)National Institutes of Health
- ClinicalTrials.gov: HIV MedicinesNational Institutes of Health
Medical subject headings
Clinicians and researchers index this subject under HIV Infections, Antiretroviral Therapy, Highly Active, Anti-HIV Agents. These are the terms to use when searching medical literature.
This page is built from the MedlinePlus health topic record for HIV Medicines, a service of the U.S. National Library of Medicine (NLM), National Institutes of Health. Information is from MedlinePlus.gov. PocketsInfo is not affiliated with, and is not endorsed by, the NLM or the NIH. Retrieved 30 July 2026.